ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection
Stock Information for ContraFect Corporation
Loading
Please wait while we load your information from QuoteMedia.